125 related articles for article (PubMed ID: 30819762)
1. Pharmacological Characterization of a Novel 5-Hydroxybenzothiazolone-Derived
Koziczak-Holbro M; Rigel DF; Dumotier B; Sykes DA; Tsao J; Nguyen NH; Bösch J; Jourdain M; Flotte L; Adachi Y; Kiffe M; Azria M; Fairhurst RA; Charlton SJ; Richardson BP; Lach-Trifilieff E; Glass DJ; Ullrich T; Hatakeyama S
J Pharmacol Exp Ther; 2019 May; 369(2):188-199. PubMed ID: 30819762
[TBL] [Abstract][Full Text] [Related]
2. A novel tissue-selective β2-adrenoceptor agonist with minimized cardiovascular effects, 5-HOB, attenuates neuropathic pain in mice.
Jourdain M; Hatakeyama S
BMC Res Notes; 2019 Jul; 12(1):413. PubMed ID: 31307541
[TBL] [Abstract][Full Text] [Related]
3. Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.
Ryall JG; Sillence MN; Lynch GS
Br J Pharmacol; 2006 Mar; 147(6):587-95. PubMed ID: 16432501
[TBL] [Abstract][Full Text] [Related]
4. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action.
Slack RJ; Barrett VJ; Morrison VS; Sturton RG; Emmons AJ; Ford AJ; Knowles RG
J Pharmacol Exp Ther; 2013 Jan; 344(1):218-30. PubMed ID: 23131596
[TBL] [Abstract][Full Text] [Related]
5. Using AAV vectors expressing the β2-adrenoceptor or associated Gα proteins to modulate skeletal muscle mass and muscle fibre size.
Hagg A; Colgan TD; Thomson RE; Qian H; Lynch GS; Gregorevic P
Sci Rep; 2016 Mar; 6():23042. PubMed ID: 26972746
[TBL] [Abstract][Full Text] [Related]
6. Expression profiling of skeletal muscle following acute and chronic beta2-adrenergic stimulation: implications for hypertrophy, metabolism and circadian rhythm.
Pearen MA; Ryall JG; Lynch GS; Muscat GE
BMC Genomics; 2009 Sep; 10():448. PubMed ID: 19772666
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action.
Battram C; Charlton SJ; Cuenoud B; Dowling MR; Fairhurst RA; Farr D; Fozard JR; Leighton-Davies JR; Lewis CA; McEvoy L; Turner RJ; Trifilieff A
J Pharmacol Exp Ther; 2006 May; 317(2):762-70. PubMed ID: 16434564
[TBL] [Abstract][Full Text] [Related]
8. The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist.
Arnold N; Beattie D; Bradley M; Brearley A; Brown L; Charlton SJ; Fairhurst RA; Farr D; Fozard J; Fullerton J; Gosling M; Hatto J; Janus D; Jones D; Jordan L; Lewis C; Maas J; McCarthy C; Mercer M; Oakman H; Press N; Profit R; Schuerch F; Sykes D; Taylor RJ; Trifilieff A; Tuffnell A
Bioorg Med Chem Lett; 2014 Sep; 24(17):4341-7. PubMed ID: 25065493
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models.
Bouyssou T; Casarosa P; Naline E; Pestel S; Konetzki I; Devillier P; Schnapp A
J Pharmacol Exp Ther; 2010 Jul; 334(1):53-62. PubMed ID: 20371707
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Profile of AZD8871 (LAS191351), a Novel Inhaled Dual M
Aparici M; Carcasona C; Ramos I; Montero JL; Otal R; Ortiz JL; Cortijo J; Puig C; Vilella D; De Alba J; Doe C; Gavaldà A; Miralpeix M
J Pharmacol Exp Ther; 2019 Jul; 370(1):127-136. PubMed ID: 31085697
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of AZD9708, a novel, selective β2-adrenoceptor agonist with rapid onset and long duration of action.
Nicholls DJ; Jordan S; Cadogan E; Lawson M; Austin RP; Paine SW; Gardiner P; Bonnert R; Connolly S; Young A
Pulm Pharmacol Ther; 2012 Aug; 25(4):293-302. PubMed ID: 22659538
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models.
Aparici M; Gómez-Angelats M; Vilella D; Otal R; Carcasona C; Viñals M; Ramos I; Gavaldà A; De Alba J; Gras J; Cortijo J; Morcillo E; Puig C; Ryder H; Beleta J; Miralpeix M
J Pharmacol Exp Ther; 2012 Aug; 342(2):497-509. PubMed ID: 22588259
[TBL] [Abstract][Full Text] [Related]
13. beta2-Adrenergic receptor stimulation in vivo induces apoptosis in the rat heart and soleus muscle.
Burniston JG; Tan LB; Goldspink DF
J Appl Physiol (1985); 2005 Apr; 98(4):1379-86. PubMed ID: 15591297
[TBL] [Abstract][Full Text] [Related]
14. Regulation of Akt-mTOR, ubiquitin-proteasome and autophagy-lysosome pathways in response to formoterol administration in rat skeletal muscle.
Joassard OR; Amirouche A; Gallot YS; Desgeorges MM; Castells J; Durieux AC; Berthon P; Freyssenet DG
Int J Biochem Cell Biol; 2013 Nov; 45(11):2444-55. PubMed ID: 23916784
[TBL] [Abstract][Full Text] [Related]
15. Long Receptor Residence Time of C26 Contributes to Super Agonist Activity at the Human β2 Adrenoceptor.
Rosethorne EM; Bradley ME; Gherbi K; Sykes DA; Sattikar A; Wright JD; Renard E; Trifilieff A; Fairhurst RA; Charlton SJ
Mol Pharmacol; 2016 Apr; 89(4):467-75. PubMed ID: 26772612
[TBL] [Abstract][Full Text] [Related]
16. Intramuscular beta2-agonist administration enhances early regeneration and functional repair in rat skeletal muscle after myotoxic injury.
Ryall JG; Schertzer JD; Alabakis TM; Gehrig SM; Plant DR; Lynch GS
J Appl Physiol (1985); 2008 Jul; 105(1):165-72. PubMed ID: 18436698
[TBL] [Abstract][Full Text] [Related]
17. Identification of Functional Food Factors as β
Chikazawa M; Sato R
J Nutr Sci Vitaminol (Tokyo); 2018; 64(1):68-74. PubMed ID: 29491275
[TBL] [Abstract][Full Text] [Related]
18. Characterization of porcine beta1- and beta2-adrenergic receptors in heart, skeletal muscle, and adipose tissue, and the identification of an atypical beta-adrenergic binding site.
Sillence MN; Hooper J; Zhou GH; Liu Q; Munn KJ
J Anim Sci; 2005 Oct; 83(10):2339-48. PubMed ID: 16160045
[TBL] [Abstract][Full Text] [Related]
19. Cardiac implications for the use of beta2-adrenoceptor agonists for the management of muscle wasting.
Molenaar P; Chen L; Parsonage WA
Br J Pharmacol; 2006 Mar; 147(6):583-6. PubMed ID: 16432500
[TBL] [Abstract][Full Text] [Related]
20. β
Campos JC; Baehr LM; Ferreira ND; Bozi LHM; Andres AM; Ribeiro MAC; Gottlieb RA; Bodine SC; Ferreira JCB
FASEB J; 2020 Apr; 34(4):5628-5641. PubMed ID: 32112488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
